SMR 2023 - The 20th International Congress of the Society for Melanoma Research
Nov 06 - Nov 09, 2023 | PhiladelphiaPAUS
LARVOL is not affiliated with The 20th International Congress of the Society for Melanoma Research and all trademarks, logos, and brand names are property of their respective owners
Showing 3 abstracts linked to Trials
Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced mucosal melanoma after progression on immune checkpoint inhibitors (ICI): Results from the phase 2 C-144-01 study
mRNA-4157/V940, an indivual neoantigen therapy, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: Efficacy, safety, and translational results from the randomized, open- label Phase 2 mRNA-4157-P201/Keynote-942 trial; Encore presentation
Adjuvant nivolumab (NIVO) v placebo (PBO) in stage IIB/C melanoma: longer follow-up from CheckMate 76K